The development of lung cancer is determined by both environmental and genetic factors. The most common environmental risk factor that is associated with lung cancer is smoking cigarettes. Therefore the contribution of both genes and smoking to the etymology of cancer made an exciting combination that was under research by a team under Dr. Yafang Li.
The Dartmouth research team identified three single-nucleotide polymorphisms (SNPs) in the human DNA that influence the human body in developing and fighting disease. The research team also conducted an interaction analysis for two SNP’s lung cancer risks for non-small cell. Another study was performed on the SNP the lung cancer risk for squamous cell. These three SNPs that the team picked out for their research are the possible biomarkers in screening for lung cancer and intervention.
The research was titled “Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in the Caucasian population.” The findings were released for publication in Carcinogenesis. The results only apply to the Caucasian population just because other ethnicities have different genetic variations from the Caucasians. The identified interaction effect will have to be repeated using the genotype from other people.
The SNPs that were studied helped to identify the level of risk to lung cancer depending on one’s smoking behavior. The findings will improve how individual risks to developing the lung cancer disease can be pinned down more accurately from their smoking behavior. This will in turn help oncologists use the most personalized treatment plan that will be predicted based on the individual’s prognosis.
The findings that have come to light on lung cancer risk concerning smoking behavior in Caucasians have been received well at Tempus. Tempus has been on the forefront in redefining the application of genome data in a clinical setting. The company has primarily built an operating system dedicated to fighting cancer. This unique organization was co-founded and is currently headed by Eric Lefkofsky. He is the author of Accelerated Disruption.
Eric Lefkosky is also a co-founding partner of a venture fund that invests in disruptive technology, Lightbank. He is the co-founder and the current chairman of the e-commerce marketplace Groupon. Eric also co-founded Uptake Technologies, which offer some of the world’s biggest industries a platform to carry out predictive analysis. He is a trustee of some institutions in Chicago. These include Lurie Children’s Hospital of Chicago, Industry and World Business Chicago and The Art Institute of Chicago.